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Abstract
Growing evidence suggests that ethanolamine plasmalogens (PlsEtns), a subtype of phospholipids, have a close
association with Alzheimer’s disease (AD). Decreased levels of PlsEtns have been commonly found in AD patients,
and were correlated with cognition deficit and severity of disease. Limited studies showed positive therapeutic
outcomes with plasmalogens interventions in AD subjects and in rodents. The potential mechanisms underlying
the beneficial effects of PlsEtns on AD may be related to the reduction of γ–secretase activity, an enzyme that
catalyzes the synthesis of β-amyloid (Aβ), a hallmark of AD. Emerging in vitro evidence also showed that PlsEtns
prevented neuronal cell death by enhancing phosphorylation of AKT and ERK signaling through the activation of
orphan G-protein coupled receptor (GPCR) proteins. In addition, PlsEtns have been found to suppress the death of
primary mouse hippocampal neuronal cells through the inhibition of caspase-9 and caspase-3 cleavages. Further in-
depth investigations are required to determine the signature molecular species of PlsEtns associated with AD,
hence their potential role as biomarkers. Clinical intervention with plasmalogens is still in its infancy but may have
the potential to be explored for a novel therapeutic approach to correct AD pathology and neural function.
Keywords: Plasmalogens, Alzheimer’s disease, Biomarker, Therapeutic efficacy, Mechanisms of action
Introduction
Plasmalogens are a subclass of phospholipids, mainly
found in the cell membranes. Ethanolamine plasmalogens
(PlsEtns) are the predominant phospholipids in the brain,
kidney, lungs and skeletal muscle [1]. They are charac-
terised by having a vinyl ether bond linking the fatty alde-
hyde to the glycerol molecule in the 1-position and a fatty
acyl bond in the 2-position. There has been an increasing
interest in plasmalogens in the last two decades due to
their biological roles in the body and association with vari-
ous diseases. It has been reported that reduced levels of
PlsEtns in the plasma are associated with Alzheimer’s dis-
ease (AD), cardiovascular disease, hypertension, cancer
and respiratory disease [1–7]. Several mechanisms associ-
ated with the action of PlsEtns have been suggested by
various authors, through predominantly in vitro studies.
These include helping maintaining membrane physical bi-
layer properties to facilitating membrane fusion and signal
transduction processes, including cholesterol efflux [8, 9];
preventing oxidative stress; and reducing inflammatory re-
sponse [7, 10–13].
This review focuses on the association(s) between plas-
malogens and Alzheimer’s disease. AD is a complex neu-
rodegenerative disease characterized by progressive
memory loss and cognitive impairment associated with
progressive neural cell loss predominantly observed in the
hippocampus [14, 15]. The causes and mechanisms of the
development of AD are not fully elucidated, although pro-
gressive accumulation of β-amyloid fibrils (Aβ plaques)
and abnormal forms of tau (tau tangles) within and out-
side of neurons are considered to be the neuropathological
hallmark [14, 15]. Currently, there is no established bio-
marker for AD to allow early detection of the risks for the
disease and potential intervention to prevent disease pro-
gression [16]. Although available anti-dementia agents
have shown some impacts on AD in a limited period of
time, more desirable therapeutic agents with potent effi-
cacy and long-lasting effects are needed.
The aim of this review is to provide an overview of
current knowledge of the biology of PlsEtns with an em-
phasis on their association with AD. We briefly discuss
the chemical and biological properties of PlsEtns; and
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present the most recent literature evidence on their as-
sociation with AD, their mechanisms of action and po-
tential use as a diagnostic and prognostic biomarker and
new therapeutic targets for AD.
Properties of Plasmalogens
Plasmalogens are subclass of phospholipids characterized
by the presence of a vinyl ether bond at the sn-1 position
and an ester bond at the sn-2 position of a glycerol back-
bone. The sn-1 position consists of C16:0 (palmitic acid),
C18:0 (stearic acid) or C18:1 (oleic acid) carbon chains,
and the head group is usually either ethanolamine or cho-
line, thus there are two predominant types of plasmalo-
gens, ethanolamine plasmalogens (PlsEtns) and choline
plasmalogens (PlsChos). The sn-2 position is predomin-
ately occupied by a polyunsaturated fatty acid, specifically
arachidonic acid (ARA) or docosahexaenoic acid (DHA)
[1–3, 17] (Fig. 1). Plasmalogens are found in almost all
mammalian tissues, although the highest concentrations
are found in brain, red blood cells, skeletal muscle and
spermatozoa and can represent as much as 18–20% of the
total phospholipids in cell membranes [1, 15]. Their distri-
bution and content varies significantly in different tissue/
cell types, with PlsEtns 10-fold higher than PlsChos except
in muscle [18]. Brain has the highest content of PlsEtns
and it constitutes 30mol% of total phospholipids in hu-
man brain, whereas heart muscle has a higher content of
PlsChos [3, 7, 17]. Moderate amounts of plasmalogens are
found in kidney, skeletal muscle, spleen and blood cells,
while liver shows low plasmalogen content [2]. The
unique functions of plasmalogen species in the body are
directly related to the property of the sn-1 vinyl ether
bond and the enrichment of polyunsaturated fatty acids at
the sn-2 position [1].
Phospholipids are either provided directly from the
diet or via de novo synthesis. Dietary phospholipids are
typically consumed in low amounts, about 2–5 g per
day, through the intake of almost all foods, especially
eggs, soybean, meat, fish, milk and other dairy products
[19, 20]. Dietary plasmalogens are absorbed in the intes-
tine and delivered to tissues [21] although the details of
digestion, absorption and subsequent transport of diet-
ary plasmalogens are essentially unknown. A similar
situation prevails for absorption and subsequent trans-
port of dietary diacyl phospholipids where specific de-
tails are still far from clear [22, 23]. Circulating
plasmalogens are either derived from dietary sources
and/or are synthesized mainly in the liver and gastro-
intestinal epithelium [24, 25] and are exported into the
blood via transport proteins of which low density lipo-
protein (LDL) is a major carrier [26]. From there they
are transported to the brain via a LDL
receptor-mediated transcytosis pathway [27]. Plasmalo-
gens are not only important structural phospholipids in
the cell membranes, they are also reservoirs of second-
ary messages and mediators of membrane dynamics and
involved in membrane fusion, ion transport, cholesterol
efflux, membrane-bound enzyme activity, and diffusion
of signal-transduction molecules. The biological func-
tions of plasmalogens have been well documented in the
literature [1, 2, 7–9, 28–30]. Plasmalogens are also anti-
oxidants, and have been shown to have a protective role
against oxidative stress, especially in the brain and heart
[12]. The biosynthesis of plasmalogens is initiated in per-
oxisomes and terminated in the endoplasmic reticulum
(Fig. 2) [7, 31]. Defects occurring at the synthetic process
may affect their biological functions in the body. Inher-
ited (primary) plasmalogen deficiency is rare (1/100,000)
and has been found to be associated with peroxisomal
disorders resulting from mutations /defects in the genes
involved in the synthesis of peroxisomal protein trans-
porter or enzymes required for plasmalogen syntheses
[1]. Primary plasmalogen deficiency associated with the
inherited human peroxisomal disorder, rhizomelic chon-
drodysplasia punctata (RCDP) shows deficiency of tissue
plasmalogens and results in severe disorders in multiple
organs such as brain, bone, lens, kidney and heart [17].
Secondary deficiency of plasmalogens resulting from de-
creased synthesis and/or increased degradation of plas-
malogens, was reported to be associated with metabolic
and inflammatory disorders such as cardiac diseases,
diabetes mellitus, cancer, respiratory disease and
Fig. 1 Chemical structures of Plasmalogens. R1 = palmitic acid (16:0) or stearic acid (18:0) or oleic acid (18:1). R2 = arachidonic acid (20:4) or
docosahexaenoic acid (22:6) or oleic acid (18:1) or linoleic acid (18:2). When there is no double bond in the alkyl chain in the 1-position, the
plasmalogens are referred to as alkyl plasmalogens, in contrast to when there is a double bond, as shown here, and they are referred to as
alkenyl plasmalogens
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Alzheimer’s disease [1–3, 7, 17]. Choline plasmalogens
play an important role in cardiac tissue, but represent a
minor species in most other organs thus most likely an
insignificant role in those organs.
Alzheimer’s disease
AD is a complex neurodegenerative disease character-
ized by progressive memory loss and cognitive impair-
ment [14]. It is the most common cause of dementia in
older people. It is associated with progressive neural cell
loss predominantly observed in the hippocampus. The
cause and mechanism of AD has not been fully eluci-
dated, although progressive accumulation of β-amyloid
fibrils (Aβ plaques) and abnormal forms of tau (tau tan-
gles) within and outside of neurons are considered to be
the neuropathological hallmarks [14, 15, 32–34]. A num-
ber of other neuropathologies of AD have also been sug-
gested including neuronal shrinkage, hypomyelination,
neuroinflammation, mitochondrial oxidative stress,
endoplasmic reticulum stress, and cholinergic dysfunc-
tion [1, 3, 35–37]. Various risk factors promote patho-
logical changes well before the onset of clinical
symptoms of AD and this includes age; cardiovascular
risk; lifestyle related factors such as obesity, diabetes, de-
pression, smoking, and insufficient diet; family history
and possibly genetic factors; environmental factors (alu-
minium and or zinc accumulation in the brain), serious
head injury [1, 14]. It is estimated that the prevalence of
AD may reach to 74 million worldwide by 2030 [38],
therefore early diagnosis and effective treatment are cru-
cial in order to reduce the incidence of the disease.
However, as the pathology of AD begins well before
symptoms are manifested, the progressive neurodegener-
ation and neural cell loss in the brain are often neglected
until impairments in cognitive performance become no-
ticeable [14]. When the loss of neuronal cells reaches a
critical point with cognition deficit, approximately 50 to
80% of cells have already died, a condition that the
course of the disease progression becomes difficult or
impossible to be changed. Currently, there are no estab-
lished biomarkers for AD to allow early detection of the
risks for the disease and potential intervention to pre-
vent disease progression [16]. Among several factors be-
ing studied as possible biomarkers for AD are the
amyloid-β in the brain as shown in positron emission
tomography (PET) imaging and levels of certain proteins
in fluid (for example, levels of Aβ and phosphorylated
tau, a major microtubule associated protein of a mature
neuron) in the cerebrospinal fluid and levels of particu-
lar groups of proteins in blood) [14]. However, those
tests are either invasive or costly. The sensitivity of those
tests also reflect imperfection for clinical diagnosis [39].
There is also no effective treatment for AD although
some anti-dementia agents such as cholinesterase inhibi-
tors and Memantine (Namenda) have shown some im-
provements in cognition, global function and /or
activities of daily living in some patients with AD for a
limited period of time [40, 41].
Fig. 2 Biosynthetic pathway of Plasmalogens. Abbreviations: DHAP, dihydroxyacetone phosphate; DHAPAT, dihydroxyacetone phosphate
acyltransferase; DHAP, dihydroxyacetone phosphate; ADHAP-S, alkyl dihydroxyacetone phosphate synthase; FAR1/2, acyl-CoA reductase 1 and 2
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Association of PlsEtns with Alzheimer’s disease
and their potential use as a biomarker
There are increasing numbers of studies in the last two
decades which have reported a direct link of plasmalo-
gen deficiency and AD. Since the first study showing a
significant deficiency of PlsEtns relative to PE in the
post-mortem brain samples of AD patients was pub-
lished in 1995 [42], much attention has been devoted to
PlsEtns and their association with AD. Recent studies
have predominately focused on the potential therapeutic
role of PlsEtns and the molecular mechanisms under-
lying their beneficial effects. Table 1 summarises key
studies focusing on the relation of PlsEtns and AD, in
particular those published in the last 5 years.
It has been demonstrated that decreased levels of
PlsEtns have not only found in the post-mortem brain
samples [43–46], but also in cerebrospinal fluid [43, 47],
plasma, serum and red blood cells of AD patients [30,
48–50]. A 70% reduction of PlsEtns has been observed
in the brain of AD patients compared with healthy brain
tissues [30, 32]. The deficiency of PlsEtns in neurode-
generation was found to be specific to AD and not ob-
served at the primary site of neurodegeneration in
Huntington’s disease nor Parkinson’s diseases [3, 44]. It
was also reported that more remarkable decrease of
PlsEtns was observed in the neurodegeneration sites
such as hippocampus, temporal cortex and frontal cor-
tex, but not the cerebellum of AD brain [15, 42, 44].
Gray matter PlsEtns was found to have different fatty
acid composition from white matter PlsEtns at sn-2 pos-
ition. In white matter, the sn-2 position is dominated by
oleic acid while in gray matter docosahexaenoic acid
(DHA, 22:6) and arachidonic acid (20:4) predominate
[3]. Furthermore, reduction of PlsEtns in different brain
tissues has been reported to be associated with different
stage of AD progression. White matter PlsEtns defi-
ciency was found to be associated with early stage of dis-
ease, and a dramatic decrease of up to 40 mol% of the
total PlsEtns has been observed in the post-mortem AD
brain [44, 51]. This decrease of PlsEtns was not corre-
lated with cognition functions [3]. While gray matter
PlsEtns deficiency has shown a correlation with the se-
verity of disease, with ~ 10mol% - 30mol% of the total
PlsEtns reduction being recorded in the post-mortem
AD brain corresponding to very mild and severe disease
status [3, 44]. Consistently, a ≤ 75% decrease of serum
plasmalogens levels in AD patients compared with
age-matched controls has also shown an association with
a cognitive function decline [30]. There have been many
reports showing that DHA is related closely to brain
functions [52–56]. Therefore, the association of gray
matter PlsEtns and white matter PlsEtns with different
stage of AD may be attributed at least in part to the dis-
crepancy in their fatty acid compositions at sn-2
position, and/or their major functions in neuronal cells
compared with myelin. Correspondingly, observations
have shown that levels of DHA and DHA-containing
PlsEtns were significantly reduced in the brain, liver,
plasma and serum of AD patients and the extent of de-
crease was correlated with cognitive deficit in AD pa-
tients [3, 24, 30, 49]. Furthermore, the severity of disease
was improved when circulating levels of DHA and plas-
malogens were high, particularly PlsEtns containing
DHA at sn-2 [30, 49].
The cause of PlsEtns deficiency in AD brain is not
clear. It is also not known whether the decrease of
PlsEtns in the patients with AD is the cause or the con-
sequence of the disease. It may be both [15], although
an earlier suggestion indicated that it may be the cause
of the ethology of AD [57]. A few possible mechanisms
with regards to the decrease of PlsEtns in AD have been
suggested including peroxisome dysfunction, oxidative
stress, alterations in membrane lipid rafts and inflamma-
tory responses [2, 3, 42, 58, 59]. Plasmalogens synthesis
is initiated in peroxisomes [31], and therefore changes/
damages in peroxisome would result in alterations in
plasmalogen synthesis. Peroxisome deficits have been re-
ported in the liver and brain of AD subjects [24, 58, 60].
A correlation was also observed between increased very
long chain fatty acids (VLCFAs: behenic acid C22:0, lig-
noceric acid C24:0 and hexacosanoic acid C26:0), de-
creased plasmalogens in AD brain, and increased
peroxisome volume density in neuronal cells [58]. All of
these VLCFAs are metabolized in peroxisomes, thus
these data again support peroxisome dysfunction in AD
[3]. Furthermore, changes in VLCFAs and PUFA- con-
taining plasmalogens also show impacts on functional
performance. An increase of VLCFAs in the cortex, and
decrease in DHA-containing plasmalogens in brain, liver
and plasma was found to be associated with cognitive
deficit in AD patients [24, 30, 44, 58].
Loss of PlsEtns in the AD brain could also be related
to oxidative stress, leading to plasmalogen degradation
by reactive oxygen species (ROS) [1]. The presence of a
vinyl–ether bond makes plasmalogens more susceptible
to oxidative stress [61]. This suggests that plasmalogens
may act as scavengers to protect other lipids and lipo-
proteins from oxidative damages [11, 62]. The antioxi-
dant effect of plasmalogens has been reported towards a
wide range of ROS [10, 59]. Reduced plasmalogens
might further enhance ongoing oxidative damage in AD,
and alter membrane properties to promote further dam-
age [1]. The lipid environment in the cell membrane
could affect amyloid precursor protein processing
through processing enzymes as they are integral mem-
brane proteins and the Aβ cleavage takes place within
the membrane. In addition, increased membrane free
cholesterol associated with PlsEtns deficiency increased
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Table 1 Plasmalogen (Pls) deficiency and their therapeutic use in AD and related disorders, and emerging molecular evidence on
their neuronal protection role
Author Design Objectives Outcomes
Human studies
Fujino et al.
2017
Patients (aged 60–85 years) with mild AD and
mild cognitive impairment (MCI) were
randomized to a multi-center, double-blind,
placebo-controlled trial to receive 24 weeks of
treatment with either: 1 mg/d purified plasmalo-
gens (Pls) extracted from scallops (n = 140), or pla-
cebo (n = 136)
To test the efficacy of oral administration of Pls
on cognitive function and blood Pls changes in
patients with mild AD and MCI. Primary outcome:
Mini Mental State Examination-Japanese (MMSE-
J); secondary outcomes: Wechsler Memory Scale-
Revised (WMS-R), Geriatric Depression Scale-Short
Version-Japanese (GDS-S-J), and concentration of
PlsEtns in circulation.
Oral administration of Pls significantly improved
memory among female mild AD patients and
those aged below 77 years as shown in WMS-R
test.
Mild AD patients showed a significantly greater
decrease in plasma PlsEtns in the placebo group
than in the treatment group.
Wood et al.
2016
Serum samples of clinical diagnosed Late-Onset
AD (LOAD) patients (n = 90), patients with mild
cognitive impairment (MCI, n = 77), and controls
(n = 51) aged 76 = 78 were analyzed by
lipidomics.
To investigate the levels of PlsEtns and
diacylglycerols utilizing high resolution mass
spectrometry, and correlate the lipid levels with
disease.
Three patient cohorts within each clinical
diagnosis (LOAD and MCI were observed: lower
circulating PlsEtns; higher circulating
diacylglycerols; and neither of these two lipid
alterations. More patients showed low level of
PlsEtns in advanced stage of disease.
Yamashita et
al. 2016
Plasma and red blood samples of 28 AD patients
(age: 72.5 ± 1.4) and 28 normal control subjects
(age: 74.1 ± 1.3) were analyzed. Evaluation of
plasma Aβ was correlated with
phosphatidylcholine hydroperoxide (PCOOH), and
PlsEtn in the blood of patients with AD.
To investigate the interaction of Aβ, peroxidation
of phosphatidylcholine and PlsEtn in AD patients.
Plasma from patients with AD showed lower
concentrations of PlsEtn species, especially DHA-
containing PlsEtn. In addition, lower PlsEtn and
higher PCOOH levels were observed in red blood
cells (RBC) of AD patients. In both AD and control
blood samples, PCOOH levels of RBC tended to
correlate with plasma levels of Aβ40.
Wood et al.
2015
Lipidomics analysis of post-mortem cerebrospinal
fluid (CSF), frontal cortex grey matter, and sub-
jacent white matter
To define potential biomarkers that distinguishes
cognitively intact subjects from those with
incipient or established dementia; and
understands the role of brain lipids in
pathophysiology of aging and age-related cogni-
tive impairment.
Monoacylglycerols (MAG), diacylglycerols (DAG),
and fatty acid 26:0 were elevated in the grey
matter of the mild cognitive impairment (MCI)
and old dementia (OD) cohorts. PlsEtns were
decreased in the grey matter of the young
dementia (YD) and OD cohorts while and
phosphatidylethanolamines were lower in the
MCI, YD and OD cohorts.
Wood et al.
2010
The serum PlsEtns of 40 AD patients and 66
controls aged 67–89 years were analyzed and
correlated with cognitive functions using AD
assessment scale-cognitive (ADAS-Cog). Serum
PlsEtns of AD patients were retested 1 year later.
To evaluate the relation between the level of
circulating PlsEtns and cognitive function using
ADAS-Cog in AD patients in comparison with
controls.
Only subjects with serum DHA-PlsEtn ≤75% or
less of normal levels exhibited cognitive decline
over a 12 month period. There was no change in
ADAS-Cog scores among participants with normal
serum PlsEtn levels at baseline (> 75%).
Goodenowe
et al. 2007
The serum samples of 324 dementia subjects (3
groups: low, moderate and severe cognitive
impairments) were analyzed and compared with
68 cognitive normal subjects aged 50–90 years to
investigate the relations between dementia
severity and PlsEtns levels.
209 healthy subjects aged 50–95 years were
divided into 3 age groups (50–59, 60–69, and 70–
95 years) and their serum were analyzed to
determine the effect of age on PlsEtns levels.
Postmortem serum samples of subjects with AD
(n = 20) and those without AD pathology (n = 19)
were analyzed to compare the serum PlsEtns
levels.
Serum from 50 clinically diagnosed AD subjects (3
stages), who were later confirmed to have AD
upon postmortem examination were analyzed to
determine the DHA PlsEtns levels.
Serum samples of 80 Japanese AD subjects and
80 non-demented Japanese subjects living in
Japan were analyzed to determine the effect of
ethnic or environmental differences on serum
DHA PlsEtns levels in AD
To determine PlsEtns depletion in the brain of
subjects with AD; and whether decreased brain
levels of PlsEtns in AD are a centrally mediated
effect caused by Aβ accumulation or there are
much broader changes occurred.
The levels of PlsEtns species were significantly
reduced in all three groups of AD subjects, and
the decrease was correlated with the severity of
AD. Peroxisome-derived PlsEtns was also signifi-
cantly reduced in all stages of AD.
Subject % with very low PlsEtns in the 60–69 year
cohort was more than double than other two
groups.
↑ mortality rate in both AD subjects and
peroxisomal disorders with ↓ PlsEtns.
Serum PlsEtns levels were significantly reduced in
the postmortem (55%) AD subjects, and clinically
diagnosed AD subject (47%). The decrease was
related to the severity of disease.
Serum DHA-PlsEtns levels were significantly re-
duced in the AD subjects.
Han et al.
2001
Post-mortem human brain tissue and mouse
brain tissues from two animal models of AD,
APPV717F and APPsw were analyzed using
Electrospray ionization mass spectrometry (ESI/
MS)
To examine systematically plasminogen content
in cellular membranes of gray and white matter
from different regions of human subjects with a
spectrum of AD clinical dementia ratings
A dramatic decrease in PlsEtns content (up to 40
mol% of total PlsEtns) in white matter at a very
early stage of AD; a correlation of the deficiency
in gray matter PlsEtns content (10 mol% - 30
mol% deficiency) with the severity of AD (very
mild to severe); no alterations of PlsEtns content
and molecular species in cerebellar gray matter
despite dramatic alterations of PlsEtns content in
cerebellar white matter. 10 mol% deficiencies was
present in mice at age of 18 months in cerebral
cortices but not in cerebella.
Animal studies
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the production of Aβ from amyloid precursor proteins [63].
Thus decreased PlsEtns in AD may facilitate Aβ produc-
tion. Furthermore, one in vitro study has shown that Aβ ag-
gregation can be modulated by plasmalogens [64]. On the
other hand, it has also been shown that increased Aβ and
ROS reduced the expression of a rate-limiting enzyme,
alkyl-dihydroxyacetone phosphate-synthase, for plasmalo-
gens de novo synthesis, due to the dysfunction of peroxi-
somes where plasmalogens are biosynthesized, resulting in
a decrease in plasmalogen level [60]. Finally, since PlsEtns
are major endogenous lipid constituents that facilitate
membrane fusion of synaptic vesicles associated with
neurotransmitter release, loss of PlsEtns might be expected
to adversely affect synaptic structure and function, thus po-
tentially contributing to the synaptic dysfunction and
neurotransmitter depletion observed in AD [1, 3, 59].
Decreased levels of plasmalogen have been observed in
neuroinflammation and that might lead to a diminished
level due to the antioxidant properties of plasmalogens that
protect cells from oxidative stress [59]. Considerable evi-
dence has suggested that there is a connection loop between
neuroinflammation, Aβ accumulation, ROS production, and
plasmalogen deficiency [59]. Furthermore, degradation of
PlsEtns by the enzyme, plasmalogen-selective phospholipase
A2 (Pls-PLA2), releases DHA or arachidonic acid from the
sn-2 position of the glycerol backbone, and this process is
possibly activated by ceramide produced under inflamma-
tory conditions which might contribute to the loss of
PlsEtns in the brain [65, 66]. Arachidonic acid is a substrate
for the synthesis of prostaglandins, thromboxanes and leu-
kotrienes. Metabolites derived from DHA include resolvins,
maresins, docosatrienes and neuroprotectins [1, 67]. All of
these molecules regulate inflammatory responses, with ara-
chidonic acid and its derivatives involved in
pro-inflammatory processes and DHA and its derivatives in-
volving in anti-inflammatory processes [13, 55, 68] (Fig. 3).
An increasing number of studies have shown that
PlsEtns deficiency is associated with AD pathology.
These findings have led the researchers to propose a role
of these molecules as a potential biomarker for AD.
However, since decreased levels of circulating plasmalo-
gens are also found in a number of other clinical
Table 1 Plasmalogen (Pls) deficiency and their therapeutic use in AD and related disorders, and emerging molecular evidence on
their neuronal protection role (Continued)
Author Design Objectives Outcomes
Katafuchi et
al. 2012
Male C57/6 J mice (10 months old) were randomly
divided into 3 groups: Pls (20 mg/kg)
+ lipopolysaccharide (LPS), LPS, and control. Pls
were extracted from chicken breast muscle. All
treatments were for 7 days.
To elucidate the effects of Pls on
neuroinflammation and β-amyloid proteins
accumulation in the hippocampus, and changes
in hippocampal Pls content following peripheral
administration of LPS in adult mice.
Pls administration suppressed the activation of
glial cells (microglia) induced by LPS, indicating
attenuation of neuroinflammation in the
hippocampus. Pls treatment also abolished β-
amyloid proteins in the hippocampus; and sup-
pressed the reduction of Pls contents in hippo-
campus induced by LPS.
Mawatari et
al. 2012
20 male Zucker diabetic fatty (ZDF) rats aged 4
weeks were randomly divided into 2 groups (10
per group) and fed with either 0.1% PlsEtn or
control diet for 4 weeks. In addition, 18 male
Wistar rats aged 6 weeks were divided evenly into
2 groups and fed with PlsEtn or control diet for 9
weeks.
To examine the health effects of dietary PlsEtn. Supplementation with 0.1% PlsEtn in both Zucker
diabetic fatty rats and Wistar rats reduced the
plasma cholesterol and phospholipids.
Correspondingly, erythrocyte PlsEtn and
phosphatidylethanolamine were increased.
In vitro studies
Hossain et
al. 2016
Mouse neuroblastoma derived cells, (Neuro 2A, or
N2A), astrocyte cell lines (A1) and microglial cell
lines (MG6) were treated with Pls extracted from
chicken skin (96.5% PlsEtns). Primary hippocampal
neurons were prepared from E-18 embryo of
mice.
To investigate how PlsEtns enhance AKT and ERK
signaling and prevent neuronal cells.
PlsEtns activated orphan GPCR (G-protein coupled
receptor) proteins to induce ERK signaling in
neuronal cells. Overexpression of GPCRs enhanced
PlsEtns-mediated phosphorylation of ERK and Akt
in cells. The GPCRs-mediated cellular signaling
was reduced significantly when the endogenous
PlsEtns were reduced.
Hossain et
al. 2013
Neuroblastoma derived cells Neuro-2A and
astrocyte-derived cells A1 were treated with Pls
(96.5% PlsEtns).
To investigate the molecular mechanism behind
the neuronal protection of PlsEtns against
apoptotic stimuli.
PlsEtns prevent neuronal cell death by enhancing
phosphorylation of AKT and ERK signaling in
neuronal cells. They also inhibited primary mouse
hippocampal neuronal cell death induced by
nutrient deprivation which was associated with
the inhibition of caspase-9 and caspase-3
cleavages.
Onodera et
al. 2014
γ -secretase activity was measured in an in vitro
assay using yeast microsomes and reconstituted
liposomes.
To investigate the effect of PlsEtns on γ--secretase
activity in vitro.
PlsEtns reduced γ--secretase activity. Bacterial
PlsEtns preparation showed dose-dependent in-
hibition of γ -secretase activity.
Rothhaar et
al. 2012
SH-SY5Y cells, and 58 postmortem brain samples
from 37 AD patients and 21 controls aged 61–88
years were analyzed for γ-secretase activity.
For ex vivo analysis of γ-secretase activity
postnuclear fractions, 6 additional human
postmortem brains and brains of C57BI6/N
wildtype mice were also analyzed.
To determine whether PlsEtns are able to
modulate amyloid precursor protein (APP)
processing or if the reduced PlsEtns level is a
consequence of AD.
PlsEtns levels were reduced in postmortem AD
brains.
PlsEtns directly reduced γ-secretase activity in SH-
SY5Y cells, postmortem AD brains and mouse
brains.
Protein and RNA level of the secretases were
unaffected.
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disorders, including ischemic cerebrovascular disease,
hypertension, uremia, and hyperlipidemia, the utility of
PlsEtns as a biomarker for AD needs to be further stud-
ied, as suggested by Wood [3, 50]. Taken together, future
studies should focus on the determination of signature
molecular species of PlsEtns associated with AD. This
may provide specific evidence on the efficacy of PlsEtns
as a reliable biomarker for AD.
Plasmalogens as a potential therapy for AD
Several researches have focused on the plasmalogens re-
placement therapy in animals, and reported promising
outcomes. Katafuchi et al. [59] reported that intraperito-
neal administration of purified plasmalogens for 7 days
attenuated the neuroinflammation in the hippocampus
of adult male C57/6 J mice, which had been induced by
lipopolysaccharide. Plasmalogen treatment also abol-
ished Aβ protein accumulation in the hippocampus, and
this was correlated with the suppressed reduction of the
plasmalogen content in the hippocampus [59]. Feeding a
test diet containing 10 wt% of phospholipids to rats for 7
days has been found to increase plasmalogen concentra-
tion by threefold in blood plasma and by 25% in the liver
[21]. Supplementation with 0.1% PlsEtn for 4 weeks in
Fig. 3 Proposed mechanistic association of ethanolamine plasmalogens deficiency and Alzheimer’s disease. Abbreviations: Aβ, β-amyloid; PlsEtns,
ethanolamine plasmalogens; VLCFAs, very long chain fatty acids. PlsEtns have a close association with Alzheimer’s disease (AD). Decreased levels of PlsEtns
have been commonly found in AD patients, and are correlated with cognition deficit and severity of disease, although it is not known whether it is the
cause or the consequence of the disease. It has been suggested maybe it is both. A few possible mechanisms with regards to the decrease of PlsEtns in
AD have been suggested: peroxisome dysfunction, oxidative stress, alterations in membrane lipid rafts and inflammatory responses. Decreased PlsEtns may
further enhance oxidative damage and alter membrane properties in AD. This plus increased membrane free cholesterol associated with PlsEtns deficiency
could increase the production of Aβ. Aβ and reactive oxygen species could further decrease PlsEtns level. PlsEtns are major lipids facilitating membrane
fusion of synaptic vesicles associated with neurotransmitter release, thus loss of PlsEtns could potentially contribute to the synaptic dysfunction and
neurotransmitter depletion in Alzheimer’s disease. The association of decreased level of PlsEtns and neuroinflammation may be related to antioxidant
properties of plasmalogens that protect cells from oxidative stress. Neuroinflammation has been reported to be associated with Aβ accumulation
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Zucker diabetic fatty (ZDF) rats and for 9 weeks in
healthy Wistar rats reduced the plasma cholesterol and
phospholipid concentrations; corresponding with this,
an increase in erythrocyte PlsEtn and phosphatidyletha-
nolamine was observed [17]. Oral administration of plas-
malogens precursor PPI-1011 (100 mg/kg/day) to C57/6
J mice for 2 weeks restored the reduced levels of PlsEtns
in plasma and brain, and this plasmalogen restoration
was associated with a stimulated re-myelination of neur-
onal cells [57].
Little information is available on the therapeutic effi-
cacy of plasmalogens in humans, suggesting a need for
future research. A recent randomized, double-blind,
placebo-controlled clinical study [15] reported a signifi-
cant improvement in memory (as shown in Wechsler
Memory Scale-Revised test) among female patients with
mild AD aged below 77 years, after 24 weeks of oral ad-
ministration with 1 mg/day of purified plasmalogens ex-
tracted from scallops. The study was conducted in
multiple centres with a total of 276 patients (140 in the
treatment group and 136 in the placebo group) aged 60
to 85 years. Correspondingly, the plasma PlsEtn in mild
AD patients showed a significantly greater decrease in
the placebo group compared with the treatment group.
The molecular mechanisms underlying the benefi-
cial effects of PlsEtns on AD have been explored
predominantly through in vitro studies. It was found
that plasmalogens strongly reduce activity of γ–
secretase, a membrane-associated aspartic protease
that catalyzes the final step of Aβ synthesis, i.e. pro-
duce several Aβ peptides of different lengths such as
Aβ40, Aβ42 and Aβ43 [32, 46]. Increased aggrega-
tion of Aβ42 and Aβ43 can result in the deposition
of Aβ and is a common outcome of the familial AD
[69]. Studies have also shown that PlsEtns prevented
neuronal cell death by enhancing phosphorylation of pro-
tein kinase B (AKT) and extracellular signal-regulated kin-
ase (ERK) signaling in neuronal cells, and this was
through the activation of orphan GPCR (G-protein
coupled receptor) proteins. Over-expression of GPCRs en-
hanced plasmalogen-mediated phosphorylation of ERK
and AKT in neuronal cells, while GPCRs-mediated cellu-
lar signaling was reduced significantly when the endogen-
ous PlsEtns levels were reduced [70, 71]. Furthermore, the
inhibitory effect of PlsEtns on the death of primary mouse
hippocampal neuronal cells was found to be associated
with the inhibition of caspase-9 and caspase-3 cleavages,
indicating the anti-apoptotic action of PlsEtns in the brain
[71]. More in-depth animal studies are required to explore
further the molecular mechanisms associated with the ac-
tions of PlsEtns in AD in order to gain a better under-
standing of these molecules and to evaluate their use as
an effective therapeutic approach to correcting AD path-
ology and function.
Conclusion
Many studies have shown that there is a link between
PlsEtns deficiency and AD, although it is not clear
whether the decrease of PlsEtns in the patients with AD
is the cause or the consequence of the disease. Reduc-
tions of PlsEtns levels have been reported in plasma,
serum, cerebrospinal fluid and brain tissue of AD pa-
tients. This suggests PlsEtns might be a candidate as a
potential AD biomarker. However, due to the fact that
decreased levels of circulating PlsEtns are also found in
a number of other clinical disorders, further in-depth in-
vestigations are required to determine the signature mo-
lecular species of PlsEtns associated with AD. Little is
known about the clinical efficacy of plasmalogens on AD
treatment, and more intervention studies with PlsEtns
replacement therapy in AD patients are warranted given
the promising outcomes in animal studies. Future in vivo
studies of molecular mechanisms associated with actions
of PlsEtns would also help to determine the potential
use of PlsEtns as a new therapeutic agent for AD.
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